Omicron-specific Sinopharm, Sinovac COVID vaccine candidates cleared for clinical trial - Reuters.com
/cloudfront-us-east-2.images.arcpublishing.com/reuters/Z735S5HJ4VLBXDM2GRHVVRGASA.jpg)
4/16/2022 12:00:00 AM3 yearsago
COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech <a href="https://www.reuters.com/companies/SVA.O" target="_blank">(SVA.O)</a> to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said …
BEIJING, April 16 (Reuters) - COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech (SVA.O) to target the Omicron variant were approved for clinical trials in Hong Kong,… [+1621 chars]
full article...